Objective: Assessment results treatment of low risk trophoblastic neoplasia by MTX. Study Design: Between 2011 and 2013, 227 women with GTD were commenced on MTXlFA at the National hospital of obstetrics and gynecology. The 227 patients were treated initially with single-agent methotrexate 0.4 mg/kg intravenously daily for 5 days per treatment course repeated every 14 days. Results: 1/ Patients under 30 age group accounted for the largest proportion of 53.3 percent, betahCG level of patients on admission 1000 IU/L accounts for most (45.8 percent). When starting treatment, the level of betahCG is 4722.33 +/- 8524.75 UI/L, after treatment, the level of betahCG is 1.95 +/- 1.08 IU/L. BetahCG values normalized in 224 (98.7 percent) of 227 patients with MTX alone, whereas 3 (1.3 percent) of 485 patients required a change in treatment.